PK/PD-guided ceftazidime-avibactam dosing for multidrug-resistant <i>Pseudomonas aeruginosa</i> infection in a preterm infant with chylothorax and ascites: a case report. [PDF]
Yuan W, Zhao X, Liu X, Tao X, Zeng L.
europepmc +1 more source
Prevalence, Antimicrobial Susceptibility, and Molecular Characteristics of Ceftazidime-Avibactam-Resistant <i>Klebsiella pneumoniae</i> in a Chinese Hospital. [PDF]
Li J +7 more
europepmc +1 more source
Intrapulmonary penetration of ceftolozane/tazobactam and ceftazidime/avibactam administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. [PDF]
Benítez-Cano A +15 more
europepmc +1 more source
KPC-33 and ompK37 mutations: Unraveling the mechanism of ceftazidime/avibactam resistance in ST11 carbapenem-resistant Klebsiella pneumoniae. [PDF]
Zhao S +6 more
europepmc +1 more source
Ceftazidime/avibactam and aztreonam combined with an aminoglycoside combat metallo-β-lactamase-producing <i>Klebsiella pneumoniae</i>. [PDF]
Karunanidhi A +10 more
europepmc +1 more source
Ceftazidime-Avibactam in Critically Ill Patients: A Multicenter Observational Study. [PDF]
Silvia O +12 more
europepmc +1 more source
Ceftazidime-avibactam for multidrug and pandrug-resistant gram-negative infections in critically Ill children: a single-center pediatric ıntensive care experience. [PDF]
Havan M +11 more
europepmc +1 more source
Genomic characterization of ceftazidime/avibactam-resistant <i>Klebsiella pneumoniae</i>: a retrospective analysis on clinical isolates from an Italian transplant unit. [PDF]
Nicitra E +10 more
europepmc +1 more source
Antimicrobial Susceptibility of Ceftazidime-Avibactam in Clinical Isolates of Carbapenemase-Producing Enterobacterales. [PDF]
Jain S, Vyas A, Chaturvedi P.
europepmc +1 more source
Comparative efficacy of ceftolozane-tazobactam versus ceftazidime-avibactam for <i>Pseudomonas aeruginosa</i> infections: a GRADE-assessed systematic review and meta-analysis. [PDF]
Shah A +10 more
europepmc +1 more source

